Please login to the form below
Almirall
This page shows the latest Almirall news and features for those working in and with pharma, biotech and healthcare.
Almirall acquires Allergan’s dermatology portfolio for $650m
In a deal worth $650m, Spanish pharmaceutical company Almirall is set to buy Allergan’s US-based medical dermatology unit. ... If approved, Seysara could pull in predicted annual sales of $200m for Almirall.
Latest news
-
Alnylam’s amyloidosis drug heads latest crop of CHMP approvals
There was also good news for Almirall, which got the nod for its delayed interleukin-23 inhibitor Ilumetri (tildrakizumab) as a treatment for moderate to severe plaque psoriasis, although it enters
-
Alnylam’s amyloidosis drug heads latest crop of CHMP approvals
There was also good news for Almirall, which got the nod for its delayed interleukin-23 inhibitor Ilumetri (tildrakizumab) as a treatment for moderate to severe plaque psoriasis, although it enters
-
Sun Pharma passes milestone with novel psoriasis drug approval
Last November, Sun Pharma’s European licensee for tildrakizumab - Spain’s Almirall - said it expects the launch of the drug in the EU to be delayed by at least six months ... Almirall licensed European rights to the drug in July 2016 and filed for
-
Almirall looks to crowdsource new skin health treatments
Almirall looks to crowdsource new skin health treatments. Launches open innovation platform AlmirallShare. ... Spanish pharma company Almirall has set up an online open innovation platform through which it hopes to find skin health solutions.
-
Almirall launches story campaign to raise rosacea awareness
Almirall launches story campaign to raise rosacea awareness. The Red Girl highlights the negative psychological effects of the disease. ... After acquiring Poli Group in 2015, Almirall obtained a dermatology focused R&D structure including its rosacea
More from news
Approximately 13 fully matching, plus 68 partially matching documents found.
Latest Intelligence
-
Deal Watch March 2017
12. Symatese. Almirall. Development collaboration. Customised products in aesthetics. 8. AgaImmune.
-
Deal Watch December 2016
510. Nuevolution (Denmark). Almirall (Spain). Research collaboration. RORγt inhibitors for inflammatory skin diseases and psoriatic arthritis. ... $21m plus $80m equity. Biosimilars. Nuevolution. Almirall. $453m. $11.8m. Inhibitors to transcription
-
Deal Watch October 2016
$575m. $198m. 2.9. Respiratory 2014. Almirall. Products pipeline. $2, 100 milestones.
-
Deal Watch July 2016
Celyad. $311m. $12.5m. Almirall. Patagonia. $28m. $3.5m. Petra Pharma. Sprint BioScience. ... Almirall's initial expenditure has been a more modest $3.5m for this earlier stage product.
-
Stronger together
Also speaking at the eyeforpharma conference was Almirall's CEO Eduardo Sanchiz, who noted that, while patient-centricity is often talked about in the industry, “ we have difficulties putting it in
More from intelligence
Approximately 2 fully matching, plus 10 partially matching documents found.
Latest appointments
-
Almirall appoints Peter Guenter as its CEO
Almirall appoints Peter Guenter as its CEO. He joins from Sanofi where he was executive vice president. ... I am convinced he will bring what is needed to develop Almirall to the next level.”.
-
Ron Menezes joins Almirall’s Aqua Pharmaceuticals
Ron Menezes joins Almirall’ s Aqua Pharmaceuticals. He joins the US dermatology group as its president and general manager. ... Sanchiz added: “Almirall continues to consider Aqua as a very important platform in the US market to support existing and
-
ThermiGen appoints Vladimir Paul-Blanc as president
ThermiGen appoints Vladimir Paul-Blanc as president. He will also serve as the Almirall-owned firm's general manager. ... He said: “I couldn’t be more excitied to join Almirall and work with the Thermi organisation.
-
Caldan Therapeutics bolsters senior team
Most recently, Dr Connolly served as scientific leader with Almirall, based in Barcelona, Spain.
-
Red Door promotes Matt Lowe and Katy Pogson
Aldous joined Red Door in 2011 from Red Health as a senior account manager and currently leads accounts for Sanofi, MSD, Baxter, Almirall and Astellas.
More from appointments
Approximately 5 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
Solaris Health
Abbvie. Aimmune. Almirall. Ascensia. BD. Bio-Medical Research. Desitin. Ferring. Flexyfoot. Gedeon Richter.
-
HAVAS LYNX
AbbVie. Alexion. Almirall. Astellas. AstraZeneca. Bayer. Eisai. Genzyme. Janssen. Kowa. Lilly.
-
HAVAS LYNX
AbbVie. Alexion. Almirall. Astellas. AstraZeneca. Bayer. Eisai. Genzyme. Janssen. Kowa. Lilly.
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
Featured jobs
- Integrated Brand/ Digital Senior Account Director, London
-
Excellent package
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
-
Healthcare PR Senior Account Manager
-
Salary TBC
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
- Senior Medical Writer, Principal Medical Writer, Scientific Dire...
-
£40000 - £75000 Bonus Benefits
- Account Manager, Healthcare Advertising
-
£30 - 38, 000 (or -)
-
Senior Training Manager - Surrey
-
Competitive Salary &Bonus
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
- Senior Strategist/ Planner, Healthcare Marketing, London
-
Excellent package
-
Systematic Review Lead- London
-
Negotiable
-
Senior Medical Writer
-
Salary is DOE
- Account Director or Senior Account Director
-
Salary TBC
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
Subscribe to our email news alerts
- New Awards scheme for medical and scientific professionals
- Random42 Exhibiting at BioCap Conference 2018
- Bedrock scoops top prizes at Digital Awards
- After Lucentis setback, Novartis trumpets data on follow-up drug
- Labour party divided on Brexit ‘People’s Vote’
- CHMP backs Spark’s Luxturna, but rejects Sarepta again
PMHub
COUCH.
WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...
Latest intelligence
- The gene therapy revolution
- Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
Quick links
Infographics
